A Multicenter Randomized, Double Blind, Placebo- Controlled, Phase II Study to Compare Endocrine Treatment Alone Versus Endocrine Treatment With Everolimus in Patients With HR+/HER2- Metastatic Breast Cancer and Progression After Previous Treatment With Exemestane and Everolimus
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2016
At a glance
- Drugs Everolimus (Primary) ; Hormone modulators
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms Evelyn
- 31 Aug 2018 Biomarkers information updated
- 25 Jul 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 16 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.